Thermo Fisher Scientific Inc.
TMO
$574.30
-0.43%
Thermo Fisher Scientific, Inc. is a global leader in serving science, providing analytical instruments, laboratory equipment, diagnostics consumables, and life science reagents to pharmaceutical, biotech, academic, and industrial customers. The company operates through four segments—analytical technologies, specialty diagnostic products, life science solutions, and lab products and services (including CRO services)—making it a diversified and essential partner in the healthcare and research ecosystem. As the largest player in the life science tools industry, Thermo Fisher's competitive advantage lies in its broad portfolio, scale, and recurring revenue from consumables and services. The current investor narrative centers on the company's ability to sustain mid-single-digit revenue growth, expand margins through operational excellence, and navigate macroeconomic headwinds such as inflation and geopolitical tensions, as highlighted by its recent earnings beat and raised long-term guidance.…
TMO
Thermo Fisher Scientific Inc.
$574.30
Investment Opinion: Should I buy TMO Today?
Based on the analysis, TMO is rated a Buy. The thesis is that Thermo Fisher's diversified portfolio, accelerating revenue growth, and discounted valuation relative to history provide a favorable risk/reward. The consensus rating is 'Buy' with an average target of $627.62, implying 9.3% upside.
Sign up to view all
TMO 12-Month Price Forecast
The AI model assesses TMO as bullish with medium confidence. The combination of accelerating growth, discounted valuation, and strong analyst support suggests upside potential. However, the high PEG ratio and margin risks temper confidence. Upgrades would occur if growth exceeds 8% and margins expand; downgrades if growth falls below 4% or margins compress significantly.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Thermo Fisher Scientific Inc.'s 12-month outlook, with a consensus price target around $629.50 and implied upside of +9.6% versus the current price.
Average Target
$629.50
0 analysts
Implied Upside
+9.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$520 - $750
Analyst target range
Thermo Fisher is covered by 26 analysts, with a consensus recommendation of 'Buy' and a mean rating of 1.54 (where 1 is Strong Buy and 5 is Sell). The average price target is $627.62, implying an upside of approximately 9.3% from the current price of $574.30. The distribution of ratings is bullish, with no Sell ratings and a majority of Buy or Overweight ratings. Recent actions from firms like Evercore ISI, Wells Fargo, and Barclays have reaffirmed positive stances, while HSBC downgraded from Buy to Hold in June 2026, reflecting some caution. The high target of $750 suggests that some analysts see substantial upside potential, likely driven by expectations of accelerated growth from new product launches and M&A synergies. The low target of $520 implies a downside of about 9.5%, which could materialize if the company faces margin compression or a slowdown in end-market demand. The spread between high and low targets indicates moderate uncertainty, but the overall sentiment remains constructive.
Bulls vs Bears: TMO Investment Factors
Thermo Fisher presents a balanced risk/reward profile. Bullish factors include accelerating revenue growth, a forward PE below historical averages, and strong analyst support. Bearish factors include a high PEG ratio, modest growth relative to peers, and potential margin pressure. Currently, the bull case has slightly stronger evidence, given the positive earnings momentum and discounted valuation. The key tension is whether the company can sustain mid-single-digit growth and expand margins to justify its valuation. If growth accelerates further, the stock could re-rate higher; if margins compress or growth stalls, the stock may face downside.
Bullish
- Revenue Growth Accelerating: Q1 2026 revenue grew 6.18% YoY to $11.005B, up from 4.7% in Q4 2025, indicating a positive inflection. This acceleration is driven by strong demand across all segments, particularly in bioprocessing and research tools.
- Forward PE Below Historical Average: The forward PE of 20.9x is below the five-year average of ~25x, suggesting the stock is trading at a discount to its historical valuation. This implies potential upside if the market re-rates the stock to its average multiple.
- Strong Analyst Consensus and Upside: With 26 analysts, the consensus is 'Buy' (mean rating 1.54) and the average price target is $627.62, implying ~9.3% upside from the current price of $574.30. No Sell ratings and a high target of $750 indicate significant optimism.
- Robust Free Cash Flow Generation: TTM free cash flow stands at $6.748B, providing ample liquidity for debt reduction, acquisitions, and shareholder returns. This financial flexibility supports continued investment in growth initiatives.
Bearish
- High PEG Ratio Signals Overvaluation: The PEG ratio of 4.54 is elevated, suggesting that the market's growth expectations are already priced in. If growth fails to meet these expectations, the stock could face de-rating.
- Modest Revenue Growth Relative to Peers: At 6.18% YoY, revenue growth is modest compared to high-growth biotech peers. This could limit multiple expansion and make the stock less attractive to growth-oriented investors.
- Potential Margin Pressure from Inflation: Management flagged 'modest inflation' risk due to Middle East tensions, which could compress margins. Q1 2026 gross margin was 40.67%, down from 41.83% in Q3 2025, indicating early signs of pressure.
- Stock Near 52-Week High, Limited Upside: At $574.30, the stock is 89.2% of the way from its 52-week low to high, leaving limited room for upside before hitting resistance. The 52-week high of $643.99 is only 12% away, and a break above is not guaranteed.
TMO Technical Analysis
Thermo Fisher's stock is in a strong recovery phase, having rebounded sharply from its 52-week low of $435.27. Over the past year, the stock has gained 22.8%, and it currently trades at $574.30, which is 89.2% of the distance from the low to the 52-week high of $643.99. This positioning near the upper end of its range suggests renewed bullish momentum, though it also implies the stock is closer to potential resistance than to oversold levels. The 52-week high remains a key overhead level, and a break above it could signal a continuation of the uptrend, while a failure to hold recent gains might lead to a pullback toward support.
Beta
0.87
0.87x market volatility
Max Drawdown
-31.4%
Largest decline past year
52-Week Range
$435-$644
Price range past year
Annual Return
+22.8%
Cumulative gain past year
| Period | TMO Return | S&P 500 |
|---|---|---|
| 1m | +11.9% | +0.3% |
| 3m | +22.4% | +4.0% |
| 6m | -0.7% | +8.3% |
| 1y | +22.8% | +20.2% |
| ytd | -3.1% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMO Fundamental Analysis
Thermo Fisher's revenue growth has been steady, with the most recent quarter (Q1 2026) reporting revenue of $11.005 billion, up 6.18% year-over-year. This marks an acceleration from the prior quarter's 4.7% growth (Q4 2025 revenue of $12.215 billion vs. $11.395 billion in Q4 2024), indicating a positive inflection. The company's diversified segments are contributing to growth, with consumables and services (the largest revenue streams) providing a stable base. However, the growth rate remains modest relative to high-growth biotech peers, reflecting the mature nature of the life science tools market. The company's ability to sustain this trajectory will depend on continued demand for bioprocessing and research tools, as well as successful integration of acquisitions.
Quarterly Revenue
$11.0B
2026-03
Revenue YoY Growth
+6.2%
YoY Comparison
Gross Margin
40.7%
Latest Quarter
Free Cash Flow
$6.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMO Overvalued?
Given Thermo Fisher's positive net income, the appropriate primary valuation metric is the price-to-earnings (PE) ratio. The trailing PE stands at 32.6x, while the forward PE is 20.9x, implying the market expects significant earnings growth over the next year. This gap is consistent with the company's projected EPS growth, as analysts estimate EPS of $38.14 for the next fiscal year, up from the trailing twelve months' EPS of approximately $17.60. The forward PE of 20.9x is below the company's five-year average of around 25x, suggesting the stock is trading at a discount to its historical norm. However, the PEG ratio of 4.54 indicates that the growth expectations may already be priced in, warranting caution.
PE
32.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 24x~43x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a debt-to-equity ratio of 0.765, indicating moderate leverage. Interest expenses of $354M in Q1 2026 could rise if rates stay high, pressuring net income. The company's net margin of 15.1% is respectable but could be squeezed by inflation. Free cash flow of $6.748B provides a cushion, but high capital intensity and acquisition costs could strain liquidity if growth slows.
FAQ
The key risks include: 1) Margin compression from inflation, as seen in Q1 2026 gross margin of 40.67% vs. 41.83% in Q3 2025. 2) High debt levels with a debt-to-equity ratio of 0.765, which could increase interest expenses. 3) Competitive pressures from smaller, more agile biotech firms. 4) Macro risks such as geopolitical tensions and funding cuts in biotech. The most severe risk is a prolonged downturn in biotech funding, which could significantly reduce demand for TMO's products.
The 12-month forecast is moderately bullish. In the base case (50% probability), the stock is expected to reach $580-$650, aligning with the analyst average target of $627.62. In the bull case (30% probability), it could reach $650-$750 if growth accelerates. In the bear case (20% probability), it could fall to $435-$520 if growth stalls. The most likely scenario is the base case, assuming continued mid-single-digit growth and stable margins.
TMO is trading at a forward PE of 20.9x, which is below its five-year average of ~25x, suggesting it is undervalued relative to its history. However, the PEG ratio of 4.54 indicates that the market expects high growth, which may already be priced in. Compared to peers, the stock is fairly valued. The market is pricing in steady mid-single-digit growth and margin stability, which seems reasonable given the company's track record.
TMO is a good buy for investors seeking a diversified healthcare play with moderate growth and a reasonable valuation. The stock offers a 9.3% upside to the average analyst target of $627.62, and the forward PE of 20.9x is below its historical average. However, the high PEG ratio of 4.54 suggests that growth expectations are high, so investors should be prepared for volatility. It is best suited for long-term investors who can tolerate short-term fluctuations.
TMO is better suited for long-term investment due to its stable growth, strong cash flow, and defensive characteristics. The stock has a beta of 0.868, indicating lower volatility than the market, and pays a small dividend (yield 0.29%). Short-term trading could be profitable given the recent momentum, but the stock's moderate growth makes it less exciting for traders. A minimum holding period of 3-5 years is recommended to fully realize the benefits of its growth and dividend.